ライフサイエンスコーパス: drug target

1 transporter, PfFNT, as a novel antimalarial drug target.

2 ous allosteric antagonists of this important drug target.

3 parasitic protozoans is a clinically proven drug target.

4 the idea that Vav2 could represent a viable drug target.

5 A) receptor (hA(2A)AR) remains an attractive drug target.

6 l studies of how INSTIs bind to their native drug target.

7 nd highlight their potential as an antiviral drug target.

8 depression, besides serving as an important drug target.

9 by allosteric effects on the dynamics of the drug target.

10 n essential and vulnerable antimycobacterial drug target.

11 Influenza neuraminidase is an important drug target.

12 sis and is therefore an important antibiotic drug target.

13 rd a better understanding of this intriguing drug target.

14 oit its potential as an effective vaccine or drug target.

15 useful tool in further studies of TRPA1 as a drug target.

16 hysicochemical properties independent of the drug target.

17 oved anticancer drugs, and proteasome is the drug target.

18 ding complex and evaluate its potential as a drug target.

19 the discovery of CSC-specific biomarkers and drug targets.

20 requires continuous monitoring of drugs and drug targets.

21 MA-producing enzymes are therefore important drug targets.

22 e targets enriched for clinically successful drug targets.

23 nel of 168 G protein-coupled receptor (GPCR) drug targets.

24 sion of 39 genes, of which four encode known drug targets.

25 s disease pathogenesis and to identify novel drug targets.

26 i genes, deemed the strongest candidates for drug targets.

27 s growing interest in zDHHC enzymes as novel drug targets.

28 elated to neuropsychiatric processes, and to drug targets.

29 ith approved drugs and a negative set of non-drug targets.

30 ve trait loci (pQTL) and 38 encoding current drug targets.

31 hways have recently re-emerged as attractive drug targets.

32 s as well as N-methylamines and more complex drug targets.

33 opment, peptide design and identification of drug targets.

34 mical roles, membrane proteins are important drug targets.

35 fic disease conditions and identification of drug targets.

36 els, as well as the limitations of OXPHOS as drug targets.

37 ation of sensory signals implicating them as drug targets.

38 roteins represent an exciting class of novel drug targets.

39 genetic architecture of SCZ and provides new drug targets.

40 reens to identify and characterize potential drug targets.

41 retion in cancer and points toward potential drug targets.

42 ter cell state- and are the largest class of drug targets.

43 olism of certain tumors and became validated drug targets.

44 A elements represent a potent alternative as drug targets.

45 hways of vessel growth to identify potential drug targets.

46 nality, making them increasingly interesting drug targets.

47 athogenicity is the key to identifying novel drug targets.

48 ular tools has hindered the discovery of new drug targets.

49 biological pathways were mined for candidate drug targets.

50 atory and signaling genes, disease genes and drug targets.

51 AGE pathway modulation may lead to promising drug targets.

52 array of cellular signaling and act as major drug targets.

53 losis EH's have been identified as potential drug targets.

54 ch opens the possibility that LTs are useful drug-targets.

55 multi-photon microscopy studies on OBBBO and drug targeting.

56 ions on an independent set of clinical trial drug targets, achieving a high accuracy characterized by

57 Translation of modulation of drug target activity to therapeutic effect is a critical

58 rgent Myosin A motor (PfMyoA), a first order drug target against malaria.

59 ynthesis pathway is considered an attractive drug target against the rising threat of multi-drug-resi

60 despread resistance, creating a need for new drug targets against influenza virus.

61 Nearly all of the clinically relevant drugs target all GABA(A) receptor subtypes equally.

62 e classification and suggest potential novel drug targets along the neuropsychiatric spectrum.

63 Our drug-target analysis shows 1/3 of patients with germline

64 ogical inhibition, we establish LdHSP78 as a drug target and Ap5A as a potential lead for improved an

65 an SKI complex as a broad-spectrum antiviral drug target and identifies lead compounds for further de

66 n mechanisms, whereby a protein binds to the drug target and protects it from the inhibitory effects

67 that the PH domain of P-Rex1 is a tractable drug target and that these compounds might be useful for

68 us identification of novel disease-modifying drug targets and an increased appreciation of patient he

69 disease mechanisms, to predict potential new drug targets and anti-metabolites, and to identify bioma

70 of integral membrane proteins, which are key drug targets and are generally underrepresented in globa

71 the identification of novel trans-diagnostic drug targets and could help to inform future stratified

72 Identifying new drug targets and developing safe and effective drugs is

73 The network-based proximity between drug targets and disease genes can provide novel insight

74 high potential in rapidly identifying novel drug targets and drug candidates for complex diseases.

75 allenges have intensified the search for new drug targets and drugs that can benefit patients who are

76 potential and will aid the identification of drug targets and enable better prediction of off-target

77 l essential functions, identifying potential drug targets and for exploring mycobacteriophage physiol

78 ogy targets, recovered the majority of known drug targets and identifies a novel set of proteins as d

79 ng HIV infection and can be used to identify drug targets and study viral mutations.

80 manial drugs advocates identification of new drug targets and their inhibitors for visceral leishmani

81 odels of disease progression, and reveal new drug targets and therapies.

82 MS quantification of multiple drug targets and tissue proteotypes can improve clinical

83 and holds great potential to identify novel drug targets and vaccine development.

84 functional importance, identifies potential drug targets, and provides insight into the neuron subty

85 As such, these channels are attractive drug targets, and TASK-1 inhibitors are currently in cli

86 M catalyzing enzymes have become significant drug targets, and therefore, tremendous interest has bee

87 e entities studied in these two tasks (i.e., drugs, targets, and diseases) are inherently related.

88 We here present a new drug targeting approach that combines both drug classes

89 rine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious a

90 ect genetic hits are enriched for successful drug targets, as measured by historical clinical trial d

91 By providing newly predicted drug-target associations, we uncover novel opportunities

92 structures of notoriously difficult-to-study drug targets at room temperature, has now been adapted f

93 poprotein particles, and for lipid-modifying drug targets based on published genome-wide association

94 everse: estimate the magnitude of changes in drug-target binding based on antibiotic dose-response cu

95 fined test cases, our work demonstrates that drug-target binding is a major predictor of bacterial re

96 ntal biological question and investigate how drug-target binding shapes antibiotic action.

97 volves many additional effects downstream of drug-target binding.

98 ts and identifies a novel set of proteins as drug target candidates.

99 stablished anti-human immunodeficiency virus drug target, CCR5 is attracting significant additional i

100 Consistently, among 13 drugs targeting chromatin modifiers, EHMT2 inhibitors we

101 Peptide drugs targeting class B1 G-protein-coupled receptors (GP

102 learning classifiers applied to the task of drug target classification for nine different human canc

103 rtake its controlled release to the proposed drug target (colon).

104 al experiences giving insight on why certain drug-target combinations might have better perspectives

105 minent role in PD etiology, but some related drug targets could influence PD via alternate pathways.

106 is an efficient and cost-effective tool for drug target discovery and prioritization.

107 ay identify new candidates for biomarker and drug target discovery.

108 c screens have emerged as essential tools in drug target discovery.

109 The existence of relationships among drug-target-disease motivates us to jointly consider dru

110 a DNA-damage response and sensitizes Mtb to drugs targeting DNA metabolism and respiration.

111 ess conferred a therapeutic vulnerability to drugs targeting DNA-damage repair pathways.

112 ate (S1P) signaling pathway is an attractive drug target due to its involvement in immune cell chemot

113 Pharmaceutical drugs targeting dyslipidemia and cardiovascular disease

114 formation and suggests that the efficacy of drugs targeting EAD-mediated arrhythmias may depend on t

115 have been extensively investigated for their drug targeting efficiency towards the critical areas of

116 the FusB family of proteins that bind to the drug target (Elongation factor G [EF-G]) and promote dis

117 Treatments include drugs targeting energy intake, energy disposal, lipotoxi

118 e first time that TPP enables organ-specific drug target engagement and identification studies during

119 ging marker for GCGR target distribution and drug target engagement in humans.

120 Docetaxel drug-target engagement was assessed by confocal anti-tub

121 Drug-target enrichment shows pleiotropy between intracra

122 tein activated by cAMP (EPAC) is a promising drug target for a wide disease range, from neurodegenera

123 gamma-Secretase is a prime drug target for AD; however, its brain regional expressi

124 tic cup formation and might constitute a new drug target for amoebic dysentery.

125 ning protein 4 (BRD4) represents a promising drug target for anti-inflammatory therapeutics.

126 Bruton's tyrosine kinase (BTK) is a major drug target for B-cell related malignancies; however, ex

127 estrogen-related receptor alpha, a potential drug target for cancer and metabolic diseases, with its

128 The HAT domain of p300/CBP is a potential drug target for cancer.

129 rotozoan, Trypanosoma cruzi, is an important drug target for Chagas disease.

130 d inflammation, and has been considered as a drug target for chronic inflammatory diseases.

131 of cancer chemoresistance and as a potential drug target for CSC therapy.

132 C-C chemokine receptor 5 (CCR5) is a key drug target for human immunodeficiency virus, cancer, an

133 vely, these studies suggest ERalpha may be a drug target for mitigating chronic diseases in male mamm

134 suggests that the macrophage is a promising drug target for modulating the intestinal immune systems

135 eceptor transcription factor implicated as a drug target for neurological disorders including Alzheim

136 ceptor (GPCR) calcitonin receptor (CTR) is a drug target for osteoporosis and diabetes.

137 n and transcription, making it an attractive drug target for SARS-CoV-2(5,6).

138 that beta4*nAChRs provide a promising novel drug target for smoking cessation.

139 Brachyury is emerging as an exciting new drug target for the rare bone cancer chordoma.

140 sed class B G protein-coupled receptor and a drug target for the treatment of neuronal, metabolic, an

141 to induce mitophagy, and identify MCL-1 as a drug target for therapeutic intervention in Alzheimer's

142 t should be prioritized as a novel candidate drug target for treating dyslipidemia and associated CVD

143 e the major bottleneck in the search for new drug targets for AD.

144 The two receptors are established drug targets for aligning circadian phase to this cycle

145 often been used as a basis for selecting of drug targets for complex common diseases.

146 athology of schizophrenia and are attractive drug targets for individualized drug therapy trials in t

147 alization of neuron subtypes and identifying drug targets for manipulating circuit function requires

148 vant datasets, identifies numerous potential drug targets for manipulating circuit function, reveals

149 occur in higher animals, they are attractive drug targets for many bacterial diseases.

150 of ATP-gated cation channels are attractive drug targets for pain and inflammatory disease, but no s

151 d for genetically-informed prioritization of drug targets for prevention trials.

152 known signal transduction intermediates and drug targets for regulation of smooth muscle tone.

153 may lead to the identification of potential drug targets for smoking prevention and/or cessation.

154 ee amino acids from human hemoglobin and are drug targets for the design of novel antimalarial agents

155 ACATs have gained attention as potential drug targets for the treatment of diseases such as ather

156 Combined, our results reveal new potential drug targets for the treatment of tauopathies and provid

157 ue function to promote identification of new drug targets for treating obesity and related metabolic

158 hlight the potential use of S1P receptors as drug targets for treatment of Krabbe's disease.SIGNIFICA

159 ltiple ciprofloxacin-resistance mutations in drug target genes and confirmed drug resistance.

160 matter whether tumors carry mutations in the drug-targeted genes.

161 we discuss the current status of the peptide drugs targeting GPCRs, with a focus on evolving strategi

162 family of GABA(A) receptors is an important drug target group in the treatment of sleep disorders, a

163 (FQ) resistance due to mutations in the main drug targets, gyrA and parC, in all three organisms, and

164 ing and scale-up to industrial level, higher drug targeting, high drug loading, control drug release,

165 family proteins, BRD2-4 and T, are important drug targets; however, the biological functions of each

166 Identifying potential drug targets, i.e. causal protein-coding genes, therefor

167 Incorrect drug target identification is a major obstacle in drug d

168 pagation of genetic evidence can be used for drug target identification.

169 guide for exploring potential SARS-CoV-2 RNA drug targets.Importance The RNA genome of SARS-CoV-2 is

170 lation/depalmitoylation cycle as a candidate drug target in an in vivo disease-relevant model system,

171 This study highlights XPB as a novel drug target in block-and-lock therapeutic approaches.

172 e-transcription factor, ERK5, is an emerging drug target in cancer and inflammation, and small-molecu

173 hub for viral RNA synthesis and a potential drug target in CoV infection.

174 We recently validated PfCLK3 as a drug target in malaria that offers prophylactic, transmi

175 glycolytic pathway, has emerged as a useful drug target in many parasites, including Fasciola hepati

176 Thus, FAP-alpha could be a potential drug target in neutrophilic inflammatory responses to av

177 RAS and BRAF that has long been pursued as a drug target in oncology(1), and more recently in immunot

178 e I nuclear hormone receptor and the primary drug target in prostate cancer due to its role as a line

179 ism for inhibition, we provide a mechanistic drug target in RNAP.

180 brane remodeling will help to identify a new drug target in the fight against the increased antibioti

181 diated endocytosis, provide a new avenue for drug targeting in disorders with aberrant regulation of

182 tic lethality provides an avenue to discover drug targets in all these areas.

183 are key enzymes in epigenetics and important drug targets in cancer biology.

184 ible systematic screens for synthetic lethal drug targets in human cancers.

185 distribution as potential species-selective drug targets in M. tuberculosis.

186 in lung function and their potential as new drug targets in the treatment of pulmonary hypertension.

187 l gene regulation primarily impacts accurate drug target inference.

188 Rational design of pharmaceutical drugs targeting integral membrane G protein-coupled rece

189 In silico prediction of drug-target interaction can speed up the process of iden

190 Identifying drug-target interaction is a key element in drug discove

191 prediction that learns latent features from drug-target interaction network.

192 In this paper, we propose anew framework for drug-target interaction prediction that learns latent fe

193 Computational approaches for prediction of drug-target interactions (DTIs) are highly desired in co

194 Computational approaches for predicting drug-target interactions (DTIs) can provide valuable ins

195 Predicting drug-target interactions (DTIs) using human phenotypic d

196 we present computational analysis of cancer drug-target interactions affected by alternative splicin

197 ry and drug design in order to establish key drug-target interactions and fine-tune crucial drug-like

198 ulin residues and taccalonolide moieties for drug-target interactions by activity-based protein profi

199 tions of the target specificity and detailed drug-target interactions of taccalonolides, however, hav

200 ed the stability of ligand-binding poses and drug-target interactions over time.

201 tomes, that can be used to identify putative drug-target interactions without resorting to 3D modelin

202 oviding unique insights into the kinetics of drug-target interactions.

203 ng methods have been proposed for predicting drug-target interactions.

204 ay facilitate the optimal selection of novel drug targets, interpretation of early-phase clinical tri

205 decades after the successful development of drugs targeting intracellular folate metabolism, such as

206 om Aspergillus fumigatus is a fungal disease drug target involved in the production of hydroxamate-co

207 In particular, discovery of actionable drug targets is critical to developing targeted therapie

208 ap for the discovery of potential new glioma drug targets is suggested, with the goal of translating

209 st RNA viruses, and they represent potential drug targets, it is essential to chart the architectural

210 that cell phenotype dictates the response to drugs targeting lipid metabolism.

211 and screening of lung cancers, (ii) magnetic drug targeting (MDT) through either intravenous injectio

212 However, attempts to develop anti-chaperone drugs targeting molecules such as Hsp70 have been hamper

213 With respect to drug targets, most attention is focused on either the vi

214 The promising drug target N-myristoyltransferase (NMT) catalyses an es

215 Finally, drug-target network analysis reveals several potential d

216 eloped specialized FEA methods combined with drug-target network visualization tools.

217 tigational use in the clinic, relatively few drugs targeting nucleic acid sensors are approved for th

218 d novel, nuanced modulators of the A(3)AR, a drug target of growing interest.

219 searchers aims to characterize potential RNA drug targets of SCoV2.

220 xpected effects of modulating lipid-lowering drug targets on PD.

221 aspects of biological recognition sites and drug targets, opening up possibilities for pharmaceutica

222 cer treatment through action on either known drug targets or currently undrugged genes.

223 bed in MEK-ERK-driven solid tumors, in which drug-target overexpression promotes resistance but a tox

224 r, this receptor is an attractive anticancer drug target owing to the overexpression of FRalpha in a

225 an determine interaction likelihood for each drug-target pair and outperform other heuristics.

226 and identify interacting and non-interacting drug-target pairs.

227 enotypic state that no longer depends on the drug-targeted pathway.

228 The anti-cancer drug target poly(ADP-ribose) polymerase 1 (PARP1) and it

229 In silico drug target prediction provides valuable information for

230 oach can be used to make indication specific drug-target prediction by combining generic druggability

231 Computational drug repositioning and drug-target prediction have become essential tasks in th

232 s to jointly consider drug repositioning and drug-target prediction in drug discovery.

233 seamlessly integrates drug repositioning and drug-target prediction into one coherent model via cross

234 the other hand, both drug repositioning and drug-target prediction involve the same drug feature spa

235 r (NSCLC), but protein level quantitation of drug targets presents a critical problem.

236 osynthesis of epinephrine and is a potential drug target, primarily for the control of hypertension.

237 r interaction networks, including drug-drug, drug-target, protein-protein, and gene-disease interacti

238 ded PD-L1 in over half the specimens and the drug target proteins all displayed different abundance p

239 novel computational approach for predicting drug target proteins.

240 heterogeneous biological network connecting drugs, targets (proteins) and diseases.

241 e drug binding to three different classes of drug targets (receptor tyrosine kinases, nuclear hormone

242 cations for the discovery and development of drugs targeting receptors such as the calcium-sensing re

243 mplexes and their potential as antimicrobial drug targets remains unclear.

244 h optimization of cellular potency, in vitro drug-target residence times, and in vivo PK properties,

245 or new insights into pathogenesis, potential drug targets, risk stratification, response to therapy a

246 Drugs targeting S1P signaling have been remarkably succe

247 entification of WAPs can potentially benefit drug target selection and precision medicine studies.

248 f shedding and may aid in the development of drugs targeting sheddases.

249 ase (IMPDH) has been proposed as a potential drug target, since it maintains the balance between guan

250 tional specialization and identify potential drug targets specific to each neuron subtype, we perform

251 ents the ideal attributes of a promising new drug, targeting specific tissues based on chemotactic cu

252 of PP2A-inhibitors as potent antiangiogenic drugs targeting specifically nascent blood vessels with

253 ients with ADC may benefit from antifibrotic drugs targeting stromal TGFbeta1/SMAD3.

254 Omics and drug-targeting studies revealed that PI3Ks act to reduce

255 ependent RNA polymerase (RdRp), an important drug target, synthesizes viral RNA and is essential for

256 teristics suggests that some are more viable drug targets than others.

257 Sortase enzymes are attractive antivirulence drug targets that attach virulence factors to the surfac

258 Lead generation for difficult-to-drug targets that have large, featureless, and highly li

259 city in older humans and uncovered two novel drug targets that may increase vaccination efficiency in

260 Many drugs target the extracellular regions (ECRs) of cell-su

261 g hypertensive disorders when small-molecule drugs targeting the AT1R are contraindicated, for exampl

262 litate rational structure-based discovery of drugs targeting the cannabinoid system.

263 While effective anti-cancer drugs targeting the CHK1 kinase are advancing in the cli

264 Osteoporosis is currently treated with drugs targeting the differentiation or viability osteocl

265 Anti-cancer drugs targeting the DNA damage response (DDR) exploit ge

266 ead molecule to develop new antiosteoporotic drugs targeting the mechanism of osteoclast adhesion ont

267 m min(-1)) and also predicted the effects of drugs targeting the motor-clutch system or cytoskeletal

268 In recent years, a number of drugs targeting the prostate-specific membrane antigen (

269 e MRI features may be imaging biomarkers for drugs targeting the ribosome.

270 disease states to allow rational choices of drugs targeting the specific peptidase of interest.

271 in vivo screen of 16 single-agent and 41 two-drug targeted therapy combinations in mice.

272 the potential of deubiquitylating enzymes as drug targets, there is increasing demand for versatile h

273 Drugs targeting these enzymes have attracted interest fo

274 urinergic processes and development of novel drugs targeting these pathways could lead to effective t

275 fied that may be useful in the design of new drugs targeting these receptors.

276 rentiation, migration, and identity and that drugs targeting this metabolism pathway will impact on t

277 and molecular basis for future discovery of drugs targeting this TMA-producing enzyme in human gut.

278 n help to identify new or repurpose existing drugs targeting those proteins.

279 brane-localized channel represents the ideal drug target to combat APOL1-mediated kidney disease.

280 is enzyme should aid in its development as a drug target to counter Orientia infections.

281 Drug targeting to inflammatory brain pathologies such as

282 ein signaling that have emerged as promising drug targets to improve specificity and reduce side effe

283 potential to investigate novel difficult-to-drug targets, to apply predictive non-clinical models to

284 Anticancer drugs targeting TOP2 (TOP2 poisons) prevent religation o

285 our approach is able to learn sophisticated drug-target topological features and outperforms other s

286 The pharmacokinetics of nanoparticle-borne drugs targeting tumors depends critically on nanoparticl

287 ndings regarding the assessment of candidate drug targets using human loss-of-function variants.

288 biology, thus enabling pathway discovery and drug target validation across species in the field of in

289 Introduction of anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF

290 As IDOL is a putative lipid-lowering drug target, we investigated the molecular details of it

291 ration of BAT as a potential source of novel drug targets, we discuss the hypothalamic orchestration

292 ctions, some of which are known or potential drug targets, were targeted for tagging with HiBiT in mu

293 lish enterovirus RNA structures as promising drug targets while revealing an approach and mechanism o

294 creasing interest as a potential therapeutic drug target with broad clinical implications.

295 agents, including next generation anticancer drug targets with amplified effectivity.

296 e potential to identify novel biomarkers and drug targets with prognostic and therapeutic value.

297 and has recently been studied as a potential drug target, with inhibitors progressing to clinical stu

298 is of mutated glioma genes reveals potential drug targets, with several investigational drugs showing

299 To identify potential novel CVD drug targets without these adverse effects, we perform g

300 se (sChoK) has previously been proposed as a drug target, yet the effectiveness of the first and only